• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Neurology Classics

The TRANSFORMS trial: Fingolimod vs interferon in multiple sclerosis [Classics Series]

byAndrew Cheung, MD MBA
July 31, 2013
in Neurology Classics, The Classics
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. Fingolimod significantly reduced the number of relapses as compared to interferon beta-1a over a one-year period.

2. Fingolimod was associated with more transient bradycardia and a higher infection rate as compared to interferon.

Original Date of Publication: February 4, 2010

Study Rundown: In summary, patients treated with fingolimod (1.25 mg or 0.5 mg) experienced significant lower annualized relapse rates as compared to those treated with interferon beta-1a in this phase 3 study (P<0.001 for both comparisons). These findings were supported by fingolimod patients having significantly fewer new or enlarging hyperintense lesions on T2-weighted magnetic resonance imaging than patients in the interferon group. The study also demonstrated dose-dependent increases in the incidence of bradycardia and atrioventricular block with fingolimod treatment. The one-year study duration limits assessment of the long-term safety and multiple sclerosis (MS) relapse outcomes, thus longer studies are needed. While it was hoped that oral medications for MS would improve compliance, this trial found higher rates of drug discontinuation with fingolimod, compared to interferon. Notably, the TRANSFORMS trial was supported by Novartis Pharma.

Please click to read study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does TRANSFORMS apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

In-Depth [randomized, controlled study]: Originally published in 2010, the TRANSFORMS trial assessed the efficacy and safety of oral fingolimod, a sphingosine-1-phosphate-receptor modulator, compared to intramuscular interferon beta-1a in relapsing-remitting MS over a 12-month period. A total of 1,292 patients underwent randomization to receive fingolimod 1.25 mg daily, fingolimod 0.5 mg daily, or 30 µg of IM interferon beta-1a weekly.

The annualized relapse rates were 0.20 (95%CI 0.16-0.26) and 0.16 (95%CI 0.12- 0.21) for fingolimod 1.25 mg and 0.5 mg, respectively, compared to a rate of 0.33 (95%CI 0.26-0.42) for interferon beta-1a. The difference between fingolimod and interferon was significant (P<0.001) for both doses. A higher percentage of adverse events leading to drug discontinuation occurred in the high-dose fingolimod group, with a 10% discontinuation rate, versus 5.6% for the 0.5 mg fingolimod group and 3.7% for the interferon beta-1a group.

By Jose-Marc Techner, Andrew Cheung, M.D.

Trials since this one

What later trials found on the same question.

  1. 2012

    DEFINE In The Classics

    BG-12 (dimethyl fumarate) significantly reduces relapse rates, disability progression, and image detectable lesion load over a two-year period.

Citation: Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/nejmoa0907839. Epub 2010 Jan 20. PMID: 20089954.

© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD

Tags: Fingolimodinterferonmultiple sclerosisTRANSFORMS

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Neurology Classics

Previous Post

60% of food choking cases occur in children less than four years old

Next Post

Phase III trial shows survival benefit for early multiple myeloma

Next Post

Phase III trial shows survival benefit for early multiple myeloma

Emerging coronavirus found to spread in healthcare facilities

MERS remains poorly understood, deadly

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.